Free Trial
NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

BioNTech logo
$111.63 -0.03 (-0.02%)
As of 03:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About BioNTech Stock (NASDAQ:BNTX)

Key Stats

Today's Range
$110.58
$113.29
50-Day Range
$92.08
$115.64
52-Week Range
$76.53
$131.49
Volume
295,321 shs
Average Volume
941,849 shs
Market Capitalization
$26.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$137.86
Consensus Rating
Moderate Buy

Company Overview

BioNTech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

BNTX MarketRank™: 

BioNTech scored higher than 29% of companies evaluated by MarketBeat, and ranked 785th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 13 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioNTech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioNTech's stock forecast and price target.
  • Earnings Growth

    Earnings for BioNTech are expected to decrease in the coming year, from ($3.88) to ($4.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioNTech is -32.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioNTech is -32.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioNTech has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about BioNTech's valuation and earnings.
  • Percentage of Shares Shorted

    2.58% of the float of BioNTech has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNTech has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in BioNTech has recently increased by 17.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioNTech does not currently pay a dividend.

  • Dividend Growth

    BioNTech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.58% of the float of BioNTech has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNTech has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in BioNTech has recently increased by 17.50%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    BioNTech has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for BioNTech this week, compared to 12 articles on an average week.
  • Search Interest

    Only 25 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioNTech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.52% of the stock of BioNTech is held by institutions.

  • Read more about BioNTech's insider trading history.
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

BNTX Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Research Analysts Set Expectations for BioNTech Q3 Earnings
HC Wainwright Has Pessimistic View of BioNTech Q3 Earnings
BNTX - BioNTech SE ADR Dividends - Morningstar
See More Headlines

BNTX Stock Analysis - Frequently Asked Questions

BioNTech's stock was trading at $113.95 at the start of the year. Since then, BNTX shares have decreased by 2.1% and is now trading at $111.5130.

BioNTech SE Sponsored ADR (NASDAQ:BNTX) announced its earnings results on Monday, March, 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. The firm's revenue for the quarter was down 19.5% compared to the same quarter last year.
Read the conference call transcript
.

BioNTech subsidiaries include these companies: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and others.

BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Top institutional shareholders of BioNTech include Lingohr Asset Management GmbH and Gallacher Capital Management LLC.

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
3/10/2025
Today
7/09/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BNTX
CIK
1776985
Employees
6,772
Year Founded
2008

Price Target and Rating

High Price Target
$171.44
Low Price Target
$110.00
Potential Upside/Downside
+23.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
18 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$719.92 million
Pretax Margin
-28.38%

Debt

Sales & Book Value

Annual Sales
$2.98 billion
Price / Cash Flow
N/A
Book Value
$87.61 per share
Price / Book
1.27

Miscellaneous

Free Float
194,238,000
Market Cap
$26.76 billion
Optionable
Optionable
Beta
1.29

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:BNTX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners